이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

FibroGen 미래 성장

Future 기준 확인 0/6

FibroGen은 연간 수입과 매출이 각각 46.5%와 2% 증가할 것으로 예상되고 EPS는 연간 47.2%만큼 증가할 것으로 예상됩니다.

주요 정보

46.5%

수익 성장률

47.2%

EPS 성장률

Biotechs 수익 성장	24.7%
매출 성장률	2.0%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	03 Jun 2024

최근 미래 성장 업데이트

Recent updates

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Mar 22

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

Feb 05

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Dec 22

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Nov 24

Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Apr 18

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Feb 13

The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Nov 12

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Oct 09

FibroGen completes patient enrollment for Roxadustat to treat anemia in patients

Aug 26

FibroGen Q2 2022 Earnings Preview

Aug 05

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Jul 06

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Mar 31

Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook

Mar 05

Is FibroGen (NASDAQ:FGEN) Using Debt In A Risky Way?

Dec 08

News Flash: 10 Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Earnings Are Under Threat

Aug 12

Downgrade: Here's How Analysts See FibroGen, Inc. (NASDAQ:FGEN) Performing In The Near Term

Jul 17

Is FibroGen A Buy Going Into Roxa AdCom?

Jul 13

수익 및 매출 성장 예측

NasdaqGS:FGEN - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	179	-71	N/A	N/A	2
12/31/2025	152	-94	N/A	N/A	3
12/31/2024	150	-154	N/A	N/A	3
3/31/2024	167	-240	-275	-273	N/A
12/31/2023	148	-284	-318	-315	N/A
9/30/2023	155	-294	-352	-349	N/A
6/30/2023	131	-322	-319	-317	N/A
3/31/2023	116	-307	-242	-239	N/A
12/31/2022	141	-294	-185	-146	N/A
9/30/2022	123	-362	-188	-148	N/A
6/30/2022	263	-220	-118	-52	N/A
3/31/2022	258	-281	-112	-46	N/A
12/31/2021	235	-290	-112	-82	N/A
9/30/2021	284	-215	-66	-34	N/A
6/30/2021	172	-231	-85	-80	N/A
3/31/2021	190	-183	92	96	N/A
12/31/2020	176	-189	78	82	N/A
9/30/2020	119	-229	40	44	N/A
6/30/2020	108	-311	13	18	N/A
3/31/2020	257	-110	-166	-161	N/A
12/31/2019	257	-77	-84	-79	N/A
9/30/2019	357	42	-58	-51	N/A
6/30/2019	353	49	-22	-15	N/A
3/31/2019	205	-90	-28	-22	N/A
12/31/2018	213	-86	-84	-76	N/A
9/30/2018	136	-141	-68	-60	N/A
6/30/2018	147	-123	-97	-87	N/A
3/31/2018	133	-132	-81	-71	N/A
12/31/2017	131	-121	N/A	-67	N/A
9/30/2017	132	-121	N/A	-84	N/A
6/30/2017	122	-121	N/A	-67	N/A
3/31/2017	181	-64	N/A	-3	N/A
12/31/2016	183	-58	N/A	7	N/A
9/30/2016	172	-79	N/A	-14	N/A
6/30/2016	162	-100	N/A	-50	N/A
3/31/2016	193	-67	N/A	6	N/A
12/31/2015	181	-86	N/A	-19	N/A
9/30/2015	172	-85	N/A	-3	N/A
6/30/2015	167	-79	N/A	4	N/A
3/31/2015	136	-98	N/A	-4	N/A
12/31/2014	138	-60	N/A	22	N/A
9/30/2014	134	-24	N/A	24	N/A
6/30/2014	191	43	N/A	128	N/A
3/31/2014	117	-5	N/A	30	N/A
12/31/2013	102	-15	N/A	26	N/A

애널리스트 미래 성장 예측

수입 대 저축률: FGEN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: FGEN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: FGEN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: FGEN 의 수익(연간 2% ) US 시장( 8.7% 보다 느리게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: FGEN 의 수익(연간 2% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: FGEN 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

FibroGen 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Price target decreased by 17% to US$10.38

Consensus revenue estimates decrease by 13%, EPS upgraded

Price target decreased by 25% to US$19.00

Consensus EPS estimates fall by 20%, revenue upgraded

Price target increased by 16% to US$24.83

Price target increased by 21% to US$21.33

Recent updates

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

FibroGen, Inc. Announces FDA Clearance of Investigational New Drug Application for FG-3165, A Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at the 2024 American Society of Clinical Oncology Annual Meeting

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet

FibroGen, Inc. to Report Q1, 2024 Results on May 06, 2024

FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting

Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals Announce Settlement with FibroGen, Inc

Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

CEO & Director recently bought US$95k worth of stock

FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer

Full year 2023 earnings: EPS and revenues miss analyst expectations

FibroGen, Inc. to Report Q4, 2023 Results on Feb 26, 2024

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

New major risk - Financial position

FibroGen, Inc. Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Now 25% undervalued after recent price drop

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Now 30% undervalued after recent price drop

New minor risk - Financial position

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target decreased by 17% to US$10.38

FibroGen, Inc. Appoints Thane Wettig as Chief Executive Officer

Mark Eisner Resigns as Chief Medical Officer of Fibrogen, Inc., Effective September 8, 2023

Insufficient new directors

Fibrogen, Inc. Announces Topline Results from Lelantos-2, A Phase 3 Clinical Study of Pamrevlumab in Ambulatory Muscular Dystrophy

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Fibrogen, Inc. Announces Chief Executive Officer Changes

FibroGen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Consensus revenue estimates decrease by 13%, EPS upgraded

Price target decreased by 25% to US$19.00

Now 81% undervalued after recent price drop

Insider notifies of intention to sell stock

FibroGen, Inc. Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

FibroGen, Inc. Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Consensus EPS estimates fall by 20%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Insider recently sold US$124k worth of stock

CEO & Director recently sold US$1.2m worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 16% to US$24.83

FibroGen, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Price target increased by 21% to US$21.33

Price target increased to US$17.60

Chief Financial Officer notifies of intention to sell stock

Now 20% undervalued

Price target increased to US$16.40

The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Price target increased to US$16.40

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

FibroGen, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes

FibroGen completes patient enrollment for Roxadustat to treat anemia in patients

Consensus forecasts updated

Price target increased to US$14.40

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

FibroGen Q2 2022 Earnings Preview

FibroGen, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?